In a strategic alliance at the forefront of AI-driven antibody discovery, Absci has partnered with AstraZeneca to revolutionize cancer treatment research. Absci's cutting-edge Integrated Drug Creation platform, synergizing seamlessly with AstraZeneca's oncology expertise, aims to accelerate the development of an innovative cancer therapy.

Under the collaboration, Absci will leverage its pioneering generative AI technology to craft a customized therapeutic candidate antibody for a specific oncology target. The partnership includes an upfront commitment, substantial R&D funding, milestone payments, and future product sales royalties. Sean McClain, Founder & CEO of Absci, expressed enthusiasm, stating, "We are excited to collaborate with AstraZeneca to design a therapeutic candidate antibody with the potential to improve the lives of cancer patients."

Absci's Integrated Drug Creation platform combines generative AI with scalable wet-lab technologies, analyzing millions of protein-protein interactions to fuel proprietary AI models. This approach, completing the entire cycle in approximately six weeks, enhances the probability of successful development outcomes for biologic drug candidates. Puja Sapra, PhD, SVP of Biologics Engineering & Oncology Targeted Delivery at AstraZeneca, highlighted the collaboration as an "exciting opportunity to utilize Absci’s de novo AI antibody creation platform to design a potential new antibody therapy in oncology." This partnership signifies a significant step forward in demonstrating how AI can revolutionize drug discovery, following Absci's recent breakthrough in de novo antibody design using their 'zero-shot' generative AI model.